跳至主要内容
临床试验/NCT03493984
NCT03493984撤回不适用

A Preliminary Clinical Trial Investigating the Ability of Plant Exosomes to Mitigate Insulin Resistance and Chronic Inflammation in Patients Diagnosed With Polycystic Ovary Syndrome (PCOS)

University of Louisville2 个研究点 分布在 1 个国家开始时间: 2019年10月最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
试验地点
2
主要终点
Change in glucose tolerance as measured by a glucose tolerance test

研究概览

简要总结

The purpose of this study is to see if substances contained in ginger or aloe plants, called exosomes, will treat and improve the condition polycystic ovary syndrome

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 40 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Age 18-40 year
  • Patients must have a confirmed diagnosis of PCOS according to the Rotterdam Criteria. At least 2 of the following 3 characteristics must be present:
  • Oligo-anovulation
  • Clinical and/or biochemical signs of androgen excess and
  • Polycystic ovarian morphology (PCOM) (defined by an increased number of small antral follicles [≥12 follicles that were <10 mm in diameter] or an increased individual ovarian volume [>10 cm3] in 1 or both ovaries. Disorders mimicking PCOS must also be excluded, including thyroid dysfunction, hyperprolactinemia, late-onset congenital adrenal hyperplasia, and ovarian or adrenal androgen-producing tumors.
  • Of all subjects screened patients must be informed of the investigational nature of this study and give written informed consent in accordance with institutional and federal guidelines.
  • Ability to understand and willingness to sign a written informed consent document.
  • Absence of life limiting medical conditions

排除标准

  • • Pregnancy
  • Known HIV
  • Patients receiving immunosuppressive drugs
  • Patients taking confounding medications such as sex steroids, infertility medications or insulin sensitizers or any medication deemed to alter glucose and/or insulin levels
  • Active malignancy in the last 5 years
  • Patients receiving any other investigational agent(s)
  • Ginger and/or aloe allergy

结局指标

主要结局

Change in glucose tolerance as measured by a glucose tolerance test

时间窗: Baseline, twelve weeks.

A glucose challenge test will be administered after initially obtaining a fasting serum glucose(baseline), then administering a 75 gram glucose load orally, then a serum glucose will be obtained 2 hours later. Serum glucose is measured in mg/dL.

次要结局

  • Inflammatory marker Foxp3(Baseline, twelve weeks)
  • Inflammatory marker interleukin 10 (IL-10)(Baseline, twelve weeks)
  • Inflammatory marker interleukin 1b (IL-1b)(Baseline, twelve weeks)
  • Change in serum insulin levels during a glucose tolerance test(Baseline, twelve weeks)
  • Stool sample(Baseline, twelve weeks)
  • Inflammatory marker cluster of differentiation 4 (CD4)(Baseline, twelve weeks)
  • Inflammatory marker cluster of differentiation 11b (CD11b)(Baseline, twelve weeks)
  • Inflammatory marker F4/80(Baseline, twelve weeks)
  • Inflammatory marker cluster of differentiation 33 (CD33)(Baseline, twelve weeks)
  • Inflammatory marker tumor necrosis factor alpha (TNF-a)(Baseline, twelve weeks)
  • Sex hormone binding globulin(Baseline, twelve weeks)
  • Inflammatory marker cluster of differentiation 8 (CD8)(Baseline, twelve weeks)
  • Inflammatory marker interleukin 6 (IL-6)(Baseline, twelve weeks)
  • Serum Testosterone(Baseline, twelve weeks)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验